Back to Search
Start Over
Augmentation of milnacipran by risperidone in treatment for major depression
- Source :
- The International Journal of Neuropsychopharmacology. 7:55-58
- Publication Year :
- 2004
- Publisher :
- Oxford University Press (OUP), 2004.
-
Abstract
- Milnacipran, one of the serotonin noradrenaline reuptake inhibitors (SNRIs) to which venlafaxine and duloxetine belong, is a new antidepressant that has recently become available in many countries. Despite the advances in pharmacotherapy, almost one third of patients with depressive illness respond inadequately to monotherapy with such an antidepressant. We herein describe five patients with major depression who responded partially, but not fully, to milnacipran alone and remarkably improved with an adjunct of risperidone. In addition, milnacipran plus risperidone was found to be a useful augmentation for treatment-refractory depression in 3 of the 5 patients. The minimum dose of risperidone, 0.5 or 1 mg/d, was efficacious. The time of response after addition of risperidone was within 4 d. Our experience suggests that an augmentation therapy of milnacipran plus risperidone is useful for treating patients with depression who only partially respond to various types of antidepressants and for treatment-refractory depression.
- Subjects :
- Adult
Cyclopropanes
Male
medicine.medical_specialty
Venlafaxine
chemistry.chemical_compound
Pharmacotherapy
Milnacipran
medicine
Humans
Duloxetine
Pharmacology (medical)
Psychiatry
Depression (differential diagnoses)
Aged
Psychiatric Status Rating Scales
Pharmacology
Depressive Disorder, Major
Risperidone
business.industry
Middle Aged
medicine.disease
Psychiatry and Mental health
chemistry
Antidepressive Agents, Second-Generation
Major depressive disorder
Antidepressant
Drug Therapy, Combination
Female
business
Antipsychotic Agents
medicine.drug
Subjects
Details
- ISSN :
- 14695111 and 14611457
- Volume :
- 7
- Database :
- OpenAIRE
- Journal :
- The International Journal of Neuropsychopharmacology
- Accession number :
- edsair.doi.dedup.....e5d820ee38274041c817e60247058ec4